1. Home
  2. Live Updates
  3. Molnupiravir

Live Breaking News & Updates on Molnupiravir

Stay informed with the latest breaking news from Molnupiravir on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Molnupiravir and stay connected to the pulse of your community

Commentary: For some vulnerable individuals, it's as if the pandemic never ended

No matter how eager many in Singapore are to put the pandemic behind us, more can be done to protect our vulnerable from COVID-19, says infectious disease specialist Leong Hoe Nam.

Singapore , Covid-19 , Molnupiravir , Paxlovid , Elderly ,

U.S. plans shift of Merck's COVID-19 treatment to commercial market

Merck said it needs an updated letter of authorization from the U.S. Food and Drug Administration to allow it to start selling the drug commercially

United-states , Ridgeback-biotherapeutics , Pfizer , Merck-co , Administration-for-strategic-preparedness , Us-department-of-health , Drug-administration , Human-services , Log-increate-free , Strategic-preparedness , Drug , Merck

Antiviral COVID drug suspected of creating further variants

A new study raises concerns that the antiviral drug Molnupiravir could be accelerating the evolution of COVID-19 variants.

Athens , Attikír , Greece , London , City-of , United-kingdom , Theo-sanderson , Oxford-university-panoramic , Merck-co , Us-house-panel , Francis-crick-institute , Oxford-university

Covid: Warning as popular antiviral drug is driving unexpected mutations | Science | News

Molnupiravir was one of the first antivirals available on the market during the COVID-19 pandemic, and was employed by many countries, including the US, particularly against chronic infections.

London , City-of , United-kingdom , Wuhan , Hubei , China , Cambridge , Cambridgeshire , Theo-sanderson , Christopher-ruis , Ridgeback-biotherapeutics , Merck-co

COVID-19 drug may have mutated virus, study says

A drug used to treat COVID-19 may have led to mutations in the virus, a study said Monday. Pharmaceutical giant Merck's antiviral pill molnupiravir...

Canada , France , Nottingham , United-kingdom , Japan , Australia , United-states , British , Theo-sanderson , Stephen-griffin , Jonathan-ball , Uk-university-of-leeds

Molnupiravir News | Latest News

Read the latest Molnupiravir headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Lagevrio...

Molnupiravir-lagevrio , Molnupiravir , Ealth , Ifestyle ,

Cat Coronavirus Outbreak: Thousands Of Felines Die In Cyprus As Vets Turn To Human Drug For Treatment

An animal activist group estimates the virus has killed some 300,000 cats since January.


Cyprus , Israel , Turkey , Lebanon , Cypriot , Costas-himonas , Christodoulos-pipis , International-cat-day , Welfare-society , International-cat , Cat-protection , Cat

Molnupiravir and Long COVID; Shortness of Breath After COVID Infection

Also in TTHealthWatch: beta-blockers after myocardial infarction

Sweden , United-kingdom , El-paso , Texas , United-states , California , Washington , Rick-lange , Elizabeth-tracey , Texas-tech-university-health-sciences-center , Paull-foster-school-of-medicine , Johns-hopkins-medicine

Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19

A new peer-reviewed medical journal article demonstrates a functional cure for COVID-19, influenza, and RSV. ProLectin-M also eliminates symptoms.

India , Chris-turnbull , Michael-sheikh , Sheikh-linkedin , Twitter , Bioxytran-inc , Oral-galectin-inhibitor , Controlled-trial , Commercial-officer-michael-sheikh , Galectin-therapeutics , Galecto-bioscience , Sleuthing-sheikh

Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients

1. In this trial emulation study, molnupiravir and nirmatrelvir-ritonavir reduced all-cause mortality in vaccinated and unvaccinated hospitalized patients with coronavirus disease 2019 (COVID-19). 2. Molnupiravir and nirmatrelvir-ritonavir did not cause any significant reduction in intensive care unit (ICU) admissions or need for ventilatory support. Evidence Rating Level: 1 (Excellent) Study Rundown: Molnupiravir and nirmatrelvir-ritonavir have

United-states , Minute-medicine-inc , Centre-for-health-protection-of-the-government , Large-us-health-system , Drug-administration , Rating-level , United-states-food , Nirmatrelvir-plus-ritonavir , Health-protection , Hong-kong-special-administrative , Charlson-comorbidity-index